FDA to discuss J&J's canagliflozin

FDA's Endocrinologic and Metabolic Drugs Advisory Committee will meet on Jan. 10, 2013, to discuss an NDA from Johnson & Johnson (NYSE:JNJ) for Invocana canagliflozin to treat Type II diabetes. J&J su...